RATIONALE: The discriminative stimulus effects of zolpidem in squirrel monkeys trained at doses greater than or equal to 3.0 mg/kg differ from those of conventional benzodiazepines (BZs), but the extent to which these effects reflect the selectivity of zolpidem for GABA(A)/alpha(1) receptors is not known. OBJECTIVES: The present study investigated the ability of GABA(A)/alpha(1)-preferring agonists to substitute for training doses of zolpidem greater than or equal to 3.0 mg/kg and the ability of GABA(A)/alpha(1)-preferring antagonists to block zolpidem's discriminative stimulus effects. METHODS: Squirrel monkeys were trained to discriminate intravenous injections of zolpidem (3.0 or 5.6 mg/kg) from saline and tested with BZ agonists differing in selectivity and efficacy at GABA(A)/alpha(1) receptors. Antagonism of the effects of zolpidem was studied using the GABA(A)/alpha(1)-preferring antagonists beta-carboline-3-carboxylate-t-butyl ester (beta-CCT) and 3-propyloxy-beta-carboline (3-PBC). RESULTS: Zolpidem and quazepam (GABA(A)/alpha(1)-preferring agonist) engendered full substitution for zolpidem, whereas CL 218,872 (GABA(A)/alpha(1)-preferring partial agonist) and the non-selective BZ agonists alprazolam and flunitrazepam engendered low and variable levels of zolpidem-lever responding (35-58%). Both beta-CCT and 3-PBC antagonized the discriminative stimulus effects of zolpidem in a surmountable fashion. CONCLUSIONS: Our findings provide evidence for a key role of GABA(A)/alpha(1) receptors in the discriminative stimulus effects of zolpidem at relatively high training doses, and suggest that selectivity and relatively high efficacy at GABA(A)/alpha(1) receptors is required for BZ agonists to reproduce these discriminative stimulus effects.
RATIONALE: The discriminative stimulus effects of zolpidem in squirrel monkeys trained at doses greater than or equal to 3.0 mg/kg differ from those of conventional benzodiazepines (BZs), but the extent to which these effects reflect the selectivity of zolpidem for GABA(A)/alpha(1) receptors is not known. OBJECTIVES: The present study investigated the ability of GABA(A)/alpha(1)-preferring agonists to substitute for training doses of zolpidem greater than or equal to 3.0 mg/kg and the ability of GABA(A)/alpha(1)-preferring antagonists to block zolpidem's discriminative stimulus effects. METHODS: Squirrel monkeys were trained to discriminate intravenous injections of zolpidem (3.0 or 5.6 mg/kg) from saline and tested with BZ agonists differing in selectivity and efficacy at GABA(A)/alpha(1) receptors. Antagonism of the effects of zolpidem was studied using the GABA(A)/alpha(1)-preferring antagonists beta-carboline-3-carboxylate-t-butyl ester (beta-CCT) and 3-propyloxy-beta-carboline (3-PBC). RESULTS:Zolpidem and quazepam (GABA(A)/alpha(1)-preferring agonist) engendered full substitution for zolpidem, whereas CL 218,872 (GABA(A)/alpha(1)-preferring partial agonist) and the non-selective BZ agonists alprazolam and flunitrazepam engendered low and variable levels of zolpidem-lever responding (35-58%). Both beta-CCT and 3-PBC antagonized the discriminative stimulus effects of zolpidem in a surmountable fashion. CONCLUSIONS: Our findings provide evidence for a key role of GABA(A)/alpha(1) receptors in the discriminative stimulus effects of zolpidem at relatively high training doses, and suggest that selectivity and relatively high efficacy at GABA(A)/alpha(1) receptors is required for BZ agonists to reproduce these discriminative stimulus effects.
Authors: Ojas A Namjoshi; Angelica Gryboski; German O Fonseca; Michael L Van Linn; Zhi-jian Wang; Jeffrey R Deschamps; James M Cook Journal: J Org Chem Date: 2011-05-04 Impact factor: 4.354
Authors: Eileen K Sawyer; Casey Moran; Madelynn H Sirbu; Melissa Szafir; Michael Van Linn; Ojas Namjoshi; V V N Phani Babu Tiruveedhula; James M Cook; Donna M Platt Journal: Alcohol Clin Exp Res Date: 2013-12-13 Impact factor: 3.455
Authors: Angela N Duke; Donna M Platt; James M Cook; Shengming Huang; Wenyuan Yin; Bruce A Mattingly; James K Rowlett Journal: Psychopharmacology (Berl) Date: 2006-06-17 Impact factor: 4.530
Authors: Barbara J Kaminski; Michael L Van Linn; James M Cook; Wenyuan Yin; Elise M Weerts Journal: Psychopharmacology (Berl) Date: 2012-12-28 Impact factor: 4.530
Authors: Wenyuan Yin; Samarpan Majumder; Terry Clayton; Steven Petrou; Michael L VanLinn; Ojas A Namjoshi; Chunrong Ma; Brett A Cromer; Bryan L Roth; Donna M Platt; James M Cook Journal: Bioorg Med Chem Date: 2010-09-29 Impact factor: 3.641
Authors: Shannon L Gourley; Joseph F Debold; Wenyuan Yin; James Cook; Klaus A Miczek Journal: Psychopharmacology (Berl) Date: 2004-08-17 Impact factor: 4.530
Authors: Stephanie C Licata; Donna M Platt; Daniela Rüedi-Bettschen; John R Atack; Gerard R Dawson; Michael L Van Linn; James M Cook; James K Rowlett Journal: Neuropharmacology Date: 2009-10-22 Impact factor: 5.250